
Klaus-Peter Dieckmann

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4225740/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Associations of serum levels of microRNA-371a-3p (M371) with risk factors for progression in nonseminomatous testicular germ cell tumours clinical stage 1. World Journal of Urology, 2022, 40, 317-326.	2.2	8
2	Single-course bleomycin, etoposide, and cisplatin (1xBEP) as adjuvant treatment in testicular nonseminoma clinical stage 1: outcome, safety, and risk factors for relapse in a population-based study. Therapeutic Advances in Medical Oncology, 2022, 14, 175883592210868.	3.2	4
3	Serum Levels of MicroRNA-371a-3p (M371) Can Predict Absence or Presence of Vital Disease in Residual Masses After Chemotherapy of Metastatic Seminoma. Frontiers in Oncology, 2022, 12, .	2.8	7
4	High Expression of microRNA-371a-3p in Cystic Fluid of Post-Chemotherapy Teratoma with Concurrent Normal Serum Levels in Patients with Non-Seminomatous Testicular Germ Cell Tumours. Urologia Internationalis, 2021, 105, 21-26.	1.3	6
5	Serum levels of microRNA-371a-3p are not elevated in testicular tumours of non-germ cell origin. Journal of Cancer Research and Clinical Oncology, 2021, 147, 435-443.	2.5	18
6	Management of Germ Cell Tumours of the Testis in Adult Patients. German Clinical Practice Guideline Part I: Epidemiology, Classification, Diagnosis, Prognosis, Fertility Preservation, and Treatment Recommendations for Localized Stages. Urologia Internationalis, 2021, 105, 169-180.	1.3	37
7	Management of Germ Cell Tumours of the Testes in Adult Patients: German Clinical Practice Guideline, PART II – Recommendations for the Treatment of Advanced, Recurrent, and Refractory Disease and Extragonadal and Sex Cord/Stromal Tumours and for the Management of Follow-Up, Toxicity, Quality of Life. Palliative Care. and Supportive Therapy. Urologia Internationalis. 2021. 105. 181-191.	1.3	19
8	The prognostic significance of lactate dehydrogenase levels in seminoma patients with advanced disease: an analysis by the Global Germ Cell Tumor Collaborative Group (G3). World Journal of Urology, 2021, 39, 3407-3414.	2.2	4
9	Does Testicular Seminoma Involve a Higher Predisposition Than Nonseminoma to Develop Contralateral Testicular Tumors?. Journal of Clinical Oncology, 2021, 39, 1689-1690.	1.6	1
10	Revised manuscript R2, clean version are serum levels of 25-hydroxy vitamin D reduced following orchiectomy in testicular cancer patients?. Basic and Clinical Andrology, 2021, 31, 14.	1.9	4
11	Late toxicities and recurrences in patients with clinical stage I non-seminomatous germ cell tumours after 1 cycle of adjuvant bleomycin, etoposide and cisplatin versus primary retroperitoneal lymph node dissection – A 13-year follow-up analysis of a phase III trial cohort. European Journal of Cancer, 2021, 155, 64-72.	2.8	10
12	A Multi-institutional Pooled Analysis Demonstrates That Circulating miR-371a-3p Alone is Sufficient for Testicular Malignant Germ Cell Tumor Diagnosis. Clinical Genitourinary Cancer, 2021, 19, 469-479.	1.9	19
13	Circulating MicroRNAs, the Next-Generation Serum Biomarkers in Testicular Germ Cell Tumours: A Systematic Review. European Urology, 2021, 80, 456-466.	1.9	60
14	Thromboembolic Events in Patients with Testicular Germ Cell Tumours Are Predominantly Triggered by Advanced Disease and by Central Venous Access Systems. Urologia Internationalis, 2021, 105, 257-263.	1.3	5
15	Serum Level of microRNA-375-3p Is Not a Reliable Biomarker of Teratoma. In Vivo, 2020, 34, 163-168.	1.3	29
16	Major complications of post-chemotherapy retroperitoneal lymph node dissection in a contemporary cohort of patients with testicular cancer and a review of the literature. World Journal of Surgical Oncology, 2020, 18, 253.	1.9	20
17	Application of miRNAs in the diagnosis and monitoring of testicular germ cell tumours. Nature Reviews Urology, 2020, 17, 201-213.	3.8	67
18	Leydig-cell tumour of the testis: retrospective analysis of clinical and therapeutic features in 204 cases. World Journal of Urology, 2020, 38, 2857-2862.	2.2	13

KLAUS-PETER DIECKMANN

#	Article	IF	CITATIONS
19	Non-Coding microRNAs as Novel Potential Tumor Markers in Testicular Cancer. Cancers, 2020, 12, 749.	3.7	44
20	Risk Factors and Treatment Outcomes of 1,375 Patients with Testicular Leydig Cell Tumors: Analysis of Published Case Series Data. Journal of Urology, 2020, 203, 949-956.	0.4	30
21	Graded expression of microRNA-371a-3p in tumor tissues, contralateral testes, and in serum of patients with testicular germ cell tumor. Oncotarget, 2020, 11, 1462-1473.	1.8	19
22	Serum Tumour Markers in Testicular Germ Cell Tumours: Frequencies of Elevated Levels and Extents of Marker Elevation Are Significantly Associated with Clinical Parameters and with Response to Treatment. BioMed Research International, 2019, 2019, 1-22.	1.9	72
23	Adjuvant carboplatin therapy in patients with clinical stage 1 testicular seminoma: is long-term morbidity increased?. Journal of Cancer Research and Clinical Oncology, 2019, 145, 2335-2342.	2.5	9
24	Adult Granulosa Cell Tumor of the Testis: A Case Report with a Review of the Literature. Case Reports in Urology, 2019, 2019, 1-10.	0.3	5
25	Serum Levels of MicroRNA-371a-3p (M371 Test) as a New Biomarker of Testicular Germ Cell Tumors: Results of a Prospective Multicentric Study. Journal of Clinical Oncology, 2019, 37, 1412-1423.	1.6	246
26	Identification and Validation Model for Informative Liquid Biopsy-Based microRNA Biomarkers: Insights from Germ Cell Tumor In Vitro, In Vivo and Patient-Derived Data. Cells, 2019, 8, 1637.	4.1	73
27	Maligne Hodentumoren: Therapie des Primätumors. Springer Reference Medizin, 2019, , 1-9.	0.0	0
28	Keimzellneoplasie in situ (GCNIS): Therapie. Springer Reference Medizin, 2019, , 1-4.	0.0	0
29	Maligne Hodentumoren: Epidemiologie und Ätiologie. Springer Reference Medizin, 2019, , 1-8.	0.0	0
30	Maligne Hodentumoren: Onkologische Kennzeichen und Diagnostik. Springer Reference Medizin, 2019, , 1-8.	0.0	0
31	Testicular Germ-Cell Tumours: A Descriptive Analysis of Clinical Characteristics at First Presentation. Urologia Internationalis, 2018, 100, 409-419.	1.3	57
32	The Novel Biomarker of Germ Cell Tumours, Micro-RNA-371a-3p, Has a Very Rapid Decay in Patients with Clinical Stage 1. Urologia Internationalis, 2018, 100, 470-475.	1.3	60
33	Is there still a place for retroperitoneal lymph node dissection in clinical stage 1 nonseminomatous testicular germ-cell tumours? A retrospective clinical study. BMC Urology, 2018, 18, 95.	1.4	7
34	Pure Testicular Seminoma with Non-Pathologic Elevation of Alpha Fetoprotein: A Case Series. Urologia Internationalis, 2017, 99, 353-357.	1.3	8
35	Contralateral biopsies in patients with testicular germ cell tumours: What is the rationale?. World Journal of Urology, 2017, 35, 1161-1166.	2.2	0
36	Serum Levels of MicroRNA miR-371a-3p: A Sensitive and Specific New Biomarker for Germ Cell Tumours. European Urology, 2017, 71, 213-220.	1.9	161

#	Article	IF	CITATIONS
37	Pure Testicular Seminoma Relapsing Late with Somatic Type Malignancy. Case Reports in Oncological Medicine, 2017, 2017, 1-5.	0.3	1
38	Serum Levels of MicroRNA371a-3p: A Highly Sensitive Tool for Diagnosing and Staging Testicular Germ Cell Tumours: A Clinical Case Series. Urologia Internationalis, 2017, 99, 98-103.	1.3	36
39	Outcome of Men With Relapse After Adjuvant Carboplatin for Clinical Stage I Seminoma. Journal of Clinical Oncology, 2017, 35, 194-200.	1.6	41
40	Testicular seminoma clinical stage 1: treatment outcome on a routine care level. Journal of Cancer Research and Clinical Oncology, 2016, 142, 1599-1607.	2.5	48
41	Seminoma Clinical Stage 1 - Patterns of Care in Germany. Urologia Internationalis, 2016, 96, 390-398.	1.3	15
42	MicroRNA miR-371a-3p - A Novel Serum Biomarker of Testicular Germ Cell Tumors: Evidence for Specificity from Measurements in Testicular Vein Blood and in Neoplastic Hydrocele Fluid. Urologia Internationalis, 2016, 97, 76-83.	1.3	44
43	Expression of microRNAs of C19MC in Different Histological Types of Testicular Germ Cell Tumour. Cancer Genomics and Proteomics, 2016, 13, 281-9.	2.0	24
44	Testicular prostheses in patients with testicular cancer - acceptance rate and patient satisfaction. BMC Urology, 2015, 15, 16.	1.4	29
45	Factor V Leiden mutation triggering four major complications to standard dose cisplatin-chemotherapy for testicular seminoma: a case report. BMC Urology, 2015, 15, 21.	1.4	2
46	Micro <scp>RNA</scp> miRâ€371aâ€3p in serum of patients with germ cell tumours: evaluations for establishing a serum biomarker. Andrology, 2015, 3, 78-84.	3.5	79
47	Is There Still an Indication for Radiotherapy in Seminoma Clinical Stages I–IIA/B?. , 2015, , 19-24.		0
48	Changes in epidemiologic features of testicular germ cell cancer: Age at diagnosis and relative frequency of seminoma are constantly and significantly increasing. Urologic Oncology: Seminars and Original Investigations, 2014, 32, 33.e1-33.e6.	1.6	88
49	Targeted serum miRNA (TSmiR) test for diagnosis and followâ€up of (testicular) germ cell cancer patients: A proof ofÂprinciple. Molecular Oncology, 2013, 7, 1083-1092.	4.6	142
50	Paratesticular fibrous pseudotumor in young males presenting with histological features of IgG4-related disease: two case reports. Journal of Medical Case Reports, 2013, 7, 225.	0.8	28
51	Sequential bilateral testicular tumours presenting with intervals of 20Âyears and more. BMC Urology, 2013, 13, 71.	1.4	10
52	Contemporary diagnostic work-up of testicular germ cell tumours. Nature Reviews Urology, 2013, 10, 703-712.	3.8	58
53	Venous Thromboembolic Events in Germ Cell Cancer Patients Undergoing Platinum-Based Chemotherapy. Onkologie, 2013, 36, 663-668.	0.8	21
54	MicroRNAs miR-371-3 in serum as diagnostic tools in the management of testicular germ cell tumours. British Journal of Cancer, 2012, 107, 1754-1760.	6.4	148

KLAUS-PETER DIECKMANN

#	Article	IF	CITATIONS
55	Serum Levels of MicroRNAs miR-371-3: A Novel Class of Serum Biomarkers for Testicular Germ Cell Tumors?. European Urology, 2012, 61, 1068-1069.	1.9	100
56	Carboplatin Does Not Prevent Contralateral Testicular Tumors in Patients With Seminoma. Journal of Clinical Oncology, 2011, 29, 2944-2945.	1.6	3
57	Evidence for acute vascular toxicity of cisplatin-based chemotherapy in patients with germ cell tumour. Anticancer Research, 2011, 31, 4501-5.	1.1	44
58	Organ-Sparing Surgery for Adult Testicular Tumours: A Systematic Review of the Literature. European Urology, 2010, 57, 780-790.	1.9	173
59	Thrombosis of abdominal aorta during cisplatin-based chemotherapy of testicular seminoma - a case report. BMC Cancer, 2009, 9, 459.	2.6	28
60	Re: Niels J. van Casteren, Hans Stoop, Gert R. Dohle, Ronald de Wit, J. Wolter Oosterhuis, Leendert H.J. Looijenga. Noninvasive Detection of Testicular Carcinoma In Situ in Semen Using OCT3/4. Eur Urol 2008;54:153–60. European Urology, 2009, 55, e63-e64.	1.9	2
61	Is increased body mass index associated with the incidence of testicular germ cell cancer?. Journal of Cancer Research and Clinical Oncology, 2009, 135, 731-738.	2.5	32
62	Maligne Hodentumoren. , 2009, , 637-738.		0
63	European Consensus Conference on Diagnosis and Treatment of Germ Cell Cancer: A Report of the Second Meeting of the European Germ Cell Cancer Consensus group (EGCCCG): Part I. European Urology, 2008, 53, 478-496.	1.9	488
64	Randomized Phase III Trial Comparing Retroperitoneal Lymph Node Dissection With One Course of Bleomycin and Etoposide Plus Cisplatin Chemotherapy in the Adjuvant Treatment of Clinical Stage I Nonseminomatous Testicular Germ Cell Tumors: AUO Trial AH 01/94 by the German Testicular Cancer Study Group. Journal of Clinical Oncology, 2008, 26, 2966-2972.	1.6	305
65	Re: Bilateral Testicular Germ Cell Tumors in Turkey: Increase in Incidence in Last Decade and Evaluation of Risk Factors in 30 Patients. Journal of Urology, 2007, 178, 2222-2223.	0.4	2
66	Spermatogenesis in the contralateral testis of patients with testicular germ cell cancer: histological evaluation of testicular biopsies and a comparison with healthy males. BJU International, 2007, 99, 1079-1085.	2.5	44
67	Diagnosis of Contralateral Testicular Intraepithelial Neoplasia (TIN) in Patients with Testicular Germ Cell Cancer: Systematic Two-Site Biopsies Are More Sensitive Than a Single Random Biopsy. European Urology, 2007, 51, 175-185.	1.9	123
68	How Harmful is Contralateral Testicular Biopsy?—An Analysis of Serial Imaging Studies and a Prospective Evaluation of Surgical Complications. European Urology, 2005, 48, 662-672.	1.9	45
69	PREVALENCE OF TESTICULAR INTRAEPITHELIAL NEOPLASIA IN HEALTHY MALES. Journal of Urology, 2005, 173, 1577-1579.	0.4	38
70	LATE RELAPSE OF TESTICULAR GERM CELL NEOPLASMS: A DESCRIPTIVE ANALYSIS OF 122 CASES. Journal of Urology, 2005, 173, 824-829.	0.4	125
71	Four testicular biopsies failing to detect a case of testicular intraepithelial neoplasia. Acta Oncológica, 2004, 43, 212-214.	1.8	3
72	Reply to J. Bharadwa and V.H. Nargund. European Urology, 2004, 45, 392.	1.9	1

KLAUS-PETER DIECKMANN

#	Article	IF	CITATIONS
73	Diagnosis and management of testicular intraepithelial neoplasia (carcinoma in situ) - surgical aspects. Apmis, 2003, 111, 64-69.	2.0	27
74	Is Risk of Testicular Cancer Related to Body Size?. European Urology, 2002, 42, 564-569.	1.9	42
75	How Valid Is the Prenatal Estrogen Excess Hypothesis of Testicular Germ Cell Cancer?. European Urology, 2001, 40, 677-684.	1.9	41
76	Renal Actinomycosis Mimicking Renal Carcinoma. European Urology, 2001, 39, 357-359.	1.9	10
77	Carcinoma in situ in the Testis. Scandinavian Journal of Urology and Nephrology, 2000, 34, 166-186.	1.4	157
78	Adjuvant treatment of clinical Stage I seminoma: is a single course of carboplatin sufficient?. Urology, 2000, 55, 102-106.	1.0	141
79	FALSE-NEGATIVE BIOPSIES FOR TESTICULAR INTRAEPITHELIAL NEOPLASIA. Journal of Urology, 1999, 162, 364-368.	0.4	36
80	FALSE-NEGATIVE BIOPSIES FOR TESTICULAR INTRAEPITHELIAL NEOPLASIA. Journal of Urology, 1999, , 364-368.	0.4	5
81	The value of the biopsy of the contralateral testis in patients with testicular germ cell cancer: The recent German experience. Apmis, 1998, 106, 13-23.	2.0	63
82	The prevalence of familial testicular cancer. Cancer, 1997, 80, 1954-1960.	4.1	87
83	Low-dose radiation therapy for testicular intraepithelial neoplasia. Journal of Cancer Research and Clinical Oncology, 1993, 119, 355-359.	2.5	45
84	Carcinoma in situ of the testis: Intratubular germ cell neoplasia or testicular intraepithelial neoplasia?. Human Pathology, 1990, 21, 457.	2.0	40
85	Thymic hyperplasia following chemotherapy of a testicular germ cell tumor. Immunohistological evidence for a simple rebound phenomenon. Cancer, 1989, 63, 446-449.	4.1	19
86	Immunohistological determination of oestrogen receptor, progesterone receptor, and intermediate filaments in Leydig cell tumours, Leydig cell hyperplasia, and normal Leydig cells of the human testis. Journal of Pathology, 1989, 157, 225-234.	4.5	40
87	Intrascrotal Metastasis of Renal Cell Carcinoma. European Urology, 1988, 15, 297-301.	1.9	37
88	Bilateral testicular germ cell tumors. Report of nine cases and review of the literature. Cancer, 1986, 57, 1254-1258.	4.1	116
89	Serumspiegel von MicroRNA-371a-3p (M371-Test) als neuer Biomarker für testikulÃæ Keimzelltumoren: Ergebnisse einer prospektiven Multicenterstudie. Karger Kompass Onkologie, 0, , 1-10.	0.0	0